Skip to main content

Table 1 Patients' characteristics

From: Docetaxel with or without estramustine for estramustine refractory castration-resistant prostate cancer: a single institution experience

 

Docetaxel with estramustine

(n = 33)

Docetaxel without estramustine

(n = 28)

p value*

Age (years), median (range)

67 (55-88)

72 (50-82)

0.062

PSA at PCa diagnosis (ng/ml), median(range)

124.1 (10.3-4116.0)

102.1 (4.7-19523.1)

0.452

PSA at baseline (ng/ml), median(range)

17.1 (0.6-1053.0)

11.4 (0.8-618.4)

0.633

Time from diagnosis to this chemothrapy (months), median(range)

34 (4-176)

37 (7-113)

0.492

ECOG performance status, n (%)

  

0.299

   0

19 (58)

12 (43)

 

   1

9 (27)

13 (46)

 

   2

5 (15)

3 (11)

 

Gleason score, n (%)

  

0.517

   < 6

2 (6)

2 (7)

 

   7

9 (27)

4 (14)

 

   > 8

20 (61)

19 (68)

 

   unknown

2 (6)

3 (11)

 

Metastatic site, n (%)

   

   Bone

17 (52)

16 (57)

0.797

   Lymph nodes

10 (30)

11 (39)

0.590

   Liver

0 (0)

1 (4)

0.459

   Lung

3 (9)

0 (0)

0.243

   None

12 (36)

7 (25)

0.080

Prior treatment, n (%)

   

   MAB

33 (100)

28 (100)

ne

   Estramustine

33 (100)

28 (100)

ne

   Radical Prostatectomy

2 (6)

1 (4)

1.000

   Radiation Therapy

4 (12)

3 (11)

1.000

   Dexamethasone

8 (24)

11 (39)

0.270

   Other Chemotherapy

6 (18)

8 (29)

0.375

No. of cycles, median (range)

5 (2-32)

4 (2-27)

0.382

  1. * by Mann-Whitney U test and chi-square test, PSA, prostate-specific antigen; PCa, Prostate Cancer; CRPC, Castration Resistant Prostate Cancer; ECOG, Eastern Cooperative Oncology Group; MAB, Maximum Androgen Blockage; ne, not evaluable